AI Article Synopsis
- Scientists can use a special imaging technique called F-FES PET to see how many estrogen receptors are in breast cancer patients, especially those with ER-positive cancer.
- This technique helps doctors choose the best treatments, check hard-to-reach tumors, and get clear results when other tests are confusing.
- Because it's effective, the FDA has approved F-FES PET for these patients, while new tests for progesterone receptors are being tested right now.
Article Abstract
Estrogen receptor (ER)-targeted imaging with 16α-F-fluoro-17β-fluoroestradiol (F-FES) has multiple proven clinical applications for patients with ER-positive breast cancer, including helping to select optimal patients for endocrine therapies, assessing ER status in lesions that are difficult to biopsy, and evaluating lesions with inconclusive results on other imaging tests. This has led to US Food and Drug Administration approval of F-FES PET for patients with ER-positive breast cancer. Newer progesterone receptor-targeted imaging agents are in clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cpet.2023.04.008 | DOI Listing |
Publication Analysis
Top Keywords
breast cancer
12
progesterone receptor-targeted
8
pet patients
8
patients er-positive
8
er-positive breast
8
estrogen receptor-targeted
4
receptor-targeted progesterone
4
receptor-targeted pet
4
patients
4
patients breast
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!